• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 9, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

80-year-old antibiotic redesigned for new medical uses

Bioengineer by Bioengineer
October 5, 2020
in Chemistry
Reading Time: 5 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Synthetic strategy to enhance natural chemistry

IMAGE

Credit: Image by Hiroaki Itoh, first published in Nature Communications, CC-BY.

Physicians and scientists have long searched the natural world for chemicals that can improve human health. However, evolutionary selection optimized natural chemicals to benefit their host, not for safety or efficacy in humans. This mismatch inspired chemists at the University of Tokyo to alter useful natural products for better, safer use in people. Their approach has transformed one of the world’s oldest antibiotics into versions that – in preliminary lab tests – appear to be safer, stronger drugs.

Gramicidin A was originally discovered in soil bacteria and became the first commercially manufactured antibiotic in the early 1940s. It continues to be prescribed by doctors today as a topical cream or drops for some skin, eye and throat infections, but it cannot be used as a pill or injection. Gramicidin A kills bacteria by punching itself through the cell membrane, essentially allowing the cell to leak out and the world to leak in through nano-sized tunnels called ion channels. These unregulated ion channels wreak the same havoc on human cells when gramicidin A is used inside the body.

Scientists have long been fascinated by the ion channel function of gramicidin A because ion channels are nearly universal among living things. Human ion channels are involved in everything from brain function to blood pressure. About 350 artificial analogs of gramicidin A have been developed over the past 80 years, all of which have properties similar to the original and thus cannot be used in humans.

Now, a team from the University of Tokyo Department of Pharmaceutical Sciences has designed and analyzed over 4,000 gramicidin A artificial analogs.

“Usually, natural product synthesis is a very difficult, complicated task. There are many steps to make these large molecules and at the end, synthetic yields are very low, so synthetic approaches like the one bead-one compound synthesis we used are still uncommon with natural products,” said Assistant Professor Hiroaki Itoh, one of the authors of the research publication in Nature Communications.

Gramicidin A is a spiral of 15 amino acids, the building blocks of peptides, which are short proteins. Researchers strategically selected six of those amino acids that could be altered without losing essential aspects of gramicidin A’s normal structure. Each of those six amino acids could be exchanged with four different amino acids to change how the peptide bonds together, leading to a total of 4,096 variations.

The one-bead-one-compound synthesis technique begins with small glass beads serving as the foundation to attach the first amino acid. Researchers build the peptide by attaching more amino acids one at a time. Whenever they reach the point of an amino acid variation, they split the beads into equal portions corresponding to the different amino acids, then remix the beads and continue building the peptide.

After completing their synthesis, researchers placed each bead into its own container and analyzed the function of their new versions of gramicidin A.

“Actually, this was a fully manual operation. It was a struggle for the student in charge of the project, but she is a very hard worker and made a great accomplishment with this research. Considering the normal timeline of natural product chemistry, this was quick,” said Itoh. The student, Yuri Takada, who subsequently received her doctoral degree, is the first author of the research paper and is now working as a postdoctoral researcher at the University of Cambridge in the U.K.

Researchers began testing their new versions of gramicidin A for activity against the common bacterial infection streptococcus. The strongest performers were then assessed for their potential ability to not indiscriminately kill human cells by testing their reactions with rabbit blood cells and mouse leukemia cells.

These tests identified about 10 gramicidin A variations as promising future antibacterial drugs. The results also allowed researchers to identify how specific structural changes to the amino acids affect the overall function of the molecule. This foundational structure-function information is crucial for understanding why and how pharmaceuticals work.

Researchers also measured the ion channel-forming ability of the best performing new versions of gramicidin A. Although they had reduced toxicity to mammalian cells, their ion channel-forming ability remained strong. These subtle modifications to a few amino acids could transform gramicidin A’s ion channel-forming function from indiscriminate to bacteria specific.

“Most important is that this strategy can be used for other types of natural products and other ion channel-forming compounds. It has long been believed to be very difficult to realize species-selective ion channel-forming activity, but our study showed gramicidin A can have very bacteria-selective activity. I believe this thought can change the standard of ion channel-forming natural products,” said Itoh.

###

Research Article
Yuri Takada, Hiroaki Itoh, Atmika Paudel, Suresh Panthee, Hiroshi Hamamoto, Kazuhisa Sekimizu, and Masayuki Inoue. (1 Oct 2020). Discovery of Gramicidin A Analogues with Altered Activities by Multidimensional Screening of a One-Bead-One-Compound Library. Nature Communications. DOI: 10.1038/s41467-020-18711-2

Related Links
Earlier research project using the same technique on a different antibiotic: https://www.u-tokyo.ac.jp/focus/en/press/z0508_00059.html
Inoue Lab: http://www.f.u-tokyo.ac.jp/~inoue/e_index.html
Graduate School of Pharmaceutical Sciences: http://www.f.u-tokyo.ac.jp/en/

Research contact

Professor Masayuki Inoue
Email: [email protected]
Tel: +81-03-5841-1354

Press officer contacts

Ms. Caitlin Devor
Division for Strategic Public Relations, The University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo 133-8654, JAPAN
Tel: +81-080-9707-8178
E-mail: [email protected]

About the University of Tokyo
The University of Tokyo is Japan’s leading university and one of the world’s top research universities. The vast research output of some 6,000 researchers is published in the world’s top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 4,000 international students. Find out more at http://www.u-tokyo.ac.jp/en/ or follow us on Twitter at @UTokyo_News_en.

Media Contact
Professor Masayuki Inoue
[email protected]

Original Source

https://www.u-tokyo.ac.jp/focus/en/press/z0508_00136.html

Related Journal Article

http://dx.doi.org/10.1038/s41467-020-18711-2

Tags: BiochemistryBiologyChemistry/Physics/Materials SciencesMedicine/HealthMicrobiologyPharmaceutical ChemistryPharmaceutical SciencePharmaceutical Sciences
Share12Tweet8Share2ShareShareShare2

Related Posts

Bacterial Enzyme Powers ATP-Driven Protein C-Terminus Modification

Bacterial Enzyme Powers ATP-Driven Protein C-Terminus Modification

August 9, 2025
Machine-Learned Model Maps Protein Landscapes Efficiently

Machine-Learned Model Maps Protein Landscapes Efficiently

August 9, 2025

High-Definition Simulations Reveal New Class of Protein Misfolding

August 8, 2025

Organic Molecule with Dual Functions Promises Breakthroughs in Display Technology and Medical Imaging

August 8, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    136 shares
    Share 54 Tweet 34
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    77 shares
    Share 31 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    54 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

ADAR1 RNA Editing: Breast Cancer’s Molecular Insights

Comparing First-Line Treatments for Extensive-Stage SCLC

Bacterial Enzyme Powers ATP-Driven Protein C-Terminus Modification

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.